EDWARDS LIFESCIENCES CORP

NYSE: EW (Edwards Lifesciences Corporatio)

Last update: 13 Oct, 11:01PM

72.95

-0.99 (-1.34%)

  • 1D -1.34%
  • 5D -11.78%
  • 1M -4.72%
  • 6M -2.63%
  • YTD 0.50%
  • 1Y 10.95%
  • 5Y -6.51%
Previous Close 73.94
Open 73.17
Volume 3,937,506
Avg. Volume (3M) 4,500,135
Market Cap 42,828,947,456
Price / Earnings (TTM) 30.52
Price / Earnings (Forward) 27.86
Price / Sales 7.97
Price / Book 4.27
52 Weeks Range
64.89 (-11%) — 83.00 (13%)
Earnings Date 30 Oct 2025
Profit Margin 75.71%
Operating Margin (TTM) 29.01%
Diluted EPS (TTM) 2.42
Quarterly Revenue Growth (YOY) 6.20%
Quarterly Earnings Growth (YOY) 1.70%
Total Debt/Equity (MRQ) 6.86%
Current Ratio (MRQ) 4.45
Operating Cash Flow (TTM) 876.20 M
Levered Free Cash Flow (TTM) 1.45 B
Return on Assets (TTM) 8.42%
Return on Equity (TTM) 16.51%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Bearish
Stock Edwards Lifesciences Corporatio Bullish Bullish

AIStockmoo Score

2.6
Analyst Consensus 5.0
Insider Activity NA
Price Volatility -1.0
Technical Moving Averages 2.5
Technical Oscillators 4.0
Average 2.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
EW 43 B - 30.52 4.27
SNN 16 B 2.04% 32.88 2.80
BSX 154 B - 55.46 6.36
SYK 146 B 0.44% 50.87 6.61
PHG 27 B - 160.17 2.17
ABT 221 B 0.47% 15.92 4.58

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Sector Healthcare
Industry Medical Devices
Investment Style Mid Growth
% Held by Insiders 0.91%
% Held by Institutions 89.29%
52 Weeks Range
64.89 (-11%) — 83.00 (13%)
Price Target Range
84.00 (15%) — 104.00 (42%)
High 104.00 (Goldman Sachs, 42.56%) Buy
Median 95.00 (30.23%)
Low 84.00 (Canaccord Genuity, 15.15%) Hold
Average 94.31 (29.28%)
Total 10 Buy, 3 Hold
Avg. Price @ Call 82.22
Firm Date Target Price Call Price @ Call
Canaccord Genuity 03 Nov 2025 84.00 (15.15%) Hold 83.07
Truist Securities 03 Nov 2025 90.00 (23.37%) Hold 83.07
28 Oct 2025 87.00 (19.26%) Hold 82.19
Barclays 31 Oct 2025 99.00 (35.71%) Buy 82.45
Citigroup 31 Oct 2025 96.00 (31.60%) Buy 82.45
Evercore ISI Group 31 Oct 2025 92.00 (26.11%) Buy 82.45
07 Oct 2025 88.00 (20.63%) Buy 76.72
Goldman Sachs 31 Oct 2025 104.00 (42.56%) Buy 82.45
JP Morgan 31 Oct 2025 90.00 (23.37%) Hold 82.45
Mizuho 31 Oct 2025 100.00 (37.08%) Buy 82.45
Piper Sandler 31 Oct 2025 95.00 (30.23%) Buy 82.45
RBC Capital 31 Oct 2025 95.00 (30.23%) Buy 82.45
Stifel 31 Oct 2025 95.00 (30.23%) Buy 82.45
22 Sep 2025 85.00 (16.52%) Buy 73.75
Jefferies 29 Oct 2025 98.00 (34.34%) Buy 82.69
Wells Fargo 07 Aug 2025 88.00 (20.63%) Buy 77.93
Show more

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria